Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ARID1A Q1835* |
Gene Variant Detail | |
Relevant Treatment Approaches | EZH2 inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1A Q1835* ARID1A Q2115* | ovarian cancer | sensitive | Olaparib + Temozolomide | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Lynparza (olaparib) and Temodar (temozolomide) synergistically inhibited viability of an ovarian cancer cell line harboring ARID1A Q1835* and Q2115* in culture and inhibited tumor growth in a cell line xenograft model (PMID: 37306706). | 37306706 |